Elicera Therapeutics (ELIC.ST) Stock Analysis & AI Equity Report
Elicera Therapeutics (ELIC.ST) overview
Elicera Therapeutics (ELIC.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Elicera Therapeutics reported revenue of SEK 7.1m and operating profit of SEK -16.9m; the year-end share price was 1.67 SEK and market capitalisation was SEK 52.7m. Elicera Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Elicera Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Elicera Therapeutics
Elicera Therapeutics is a clinical-stage immuno-oncology company developing cell and gene therapies for cancer. Its portfolio includes CAR T-cell candidates and oncolytic virus programs, supported by the proprietary iTANK platform, which is designed to enhance immune response and broaden application across tumor types. The company also pursues out-licensing of its technology.
Generate the Elicera Therapeutics report
Elicera Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Elicera Therapeutics and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.